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Tardive dyskinesia (TD) is a movement disorder characterized by repetitive, abnormal,
persistent, purposeless, and uncontrollable movements which occur as a result of long-term use
of antipsychotic medications. Manifestations of this disorder include twisted tongue movements,
jaw movements, eye blinking, and lip smacking/puckering/pursing (Mentzel et al., 2018). Uhlyar
and Rey (2018) defined TD as a spectrum of hyperkinetic movement disorders which occur due
to the use of dopamine receptor blocking agents. Antipsychotics and neuroleptics are considered
dopamine receptor blockers and have been associated with TD.

The dopamine D2 receptor is the common target for antipsychotic medications which,
according to Seeman (2011), occupy 60-80% of these receptors in patients. First generation
antipsychotics have been implicated as posing a higher risk of developing TD than second
generation antipsychotics (Freudenreich & Remington, 2017). They have high affinity for D2
receptors, a property which enables them to remain attached to these receptors for days hence
preventing relapse. This attachment, however, can lead to TD hence the recommendation to
image and desensitize these receptors in early stage psychosis. Clozapine and quetiapine are
released from D2 receptors within 12 to 24 hours confirming why these two antipsychotic
medications don’t elicit TD (Seeman, 2011).

The actual pathophysiology of TD is unknown but there have been investigations on
dopamine receptor supersensitivity, gamma-aminobutyric acid hypofunction, and
neurodegeneration (Uhlyar & Rey, 2018). Discontinuing use of any offending agents may not be
an option especially for patients dependent on those agents to treat their underlying conditions,
doing so would also not reverse TD symptoms and this might temporarily exacerbate TD
symptoms (Atlas, Agboola, & Curfman, 2018). The Abnormal Involuntary Movement Scale
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(AIMS) is commonly used for evaluating the severity of dyskinesia in patients receiving chronic
antipsychotic therapies. According to Uhlyar and Rey (2018), incidence of TD is about 1% and
patients receiving antipsychotic therapies have a prevalence of up to 30%. The elderly, women,
African Americans, and patients receiving prolonged treatment with antipsychotics have a higher
risk of developing TD. Hansen, Nausheen, Hart, and Kingdon (2013) contended that
antipsychotics do not have to be given in large amounts to provoke high levels of extrapyramidal
side effects (EPSs). Patients are likely to develop TD even at low doses of antipsychotic
medication.

There has been no study conducted to investigate the connection between
methamphetamine use and TD in humans. A recent study in mice indicated that
methamphetamine may have long-term consequences on the nerve cells in the brain regions
responsible for cognition, memory, decision-making capacity, and movement. The striatum,
hippocampus, and the frontal cortex are the areas that are most commonly affected. It is assumed
that if this drug kills nerve cells in the same human brain regions, there could be huge
consequences. The researchers further asserted that movement disorders such as TD and
huntington’s chorea are likely to arise as a result of loss of striatal cells and DNA fragmentation.
Imaging studies on human brains of methamphetamine abusers have indicated extensive damage
to nerve endings of cells that contain dopamine. This damage persists for at least three years after
these individuals have stopped using the drug. This drug also leads to death of other nerve cells
that produce other neurotransmitters in the brain (Mathias, 2000).

Alcohol and cannabis use have been found to contribute to TD and other EPSs in
individuals with or without schizophrenia. These two, along with other illicit chemicals increase
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vulnerability to movement disorders. Occasional alcohol use has not been found to contribute to
TD symptoms but use that has reached the point of treatment has been found to be contributory
not only to TD symptoms but also other negative schizophrenia symptoms (Swofford, SchellerGilkey, Miller, Woolwine, & Mance, 2000). Seeman (2011) noted that use of dopamine-like
drugs such as cocaine lead to elevation of D2 receptors which consequently increase TD
symptoms. No correlation has been found between smoking and EPSs (Hansen et al., 2013).
This case study focuses on a 53-year-old, Caucasian, divorced man admitted to the
hospital from jail. He was adjudicated not competent to proceed with respect to felony charges of
attempting to disarm a peace officer, fleeing a peace officer in a motor vehicle, and assault on a
peace officer, 4th Degree. This stemmed from events that occurred in late May when the patient
allegedly behaved in a suspicious manner, watching a woman and her children from his truck.
When approached by law enforcement, he was noted to be pacing and behaving in an agitated
manner, and then allegedly lashed out at officers in the course of attempts to detain him resulting
in use of a taser. He was reportedly arrested after a high-speed chase involving multiple law
enforcement agencies. While jailed, he was housed in administrative segregation, although his
behavior was described as increasingly calm and pleasant following the initial period of
disorganized behavior, refusal to follow directions from correctional officers and hostile, labile
affect. He reportedly harbored delusional beliefs about the devil and believed he was vulnerable
to receiving messages from spirits near him. Records documented a positive drug screen for
methamphetamine and (tetrahydrocannabinol) THC upon arrest.
Records indicated a pattern of exacerbated psychotic symptoms, predominantly
hallucinations, delusional thinking, disorganized speech and erratic, disorganized behavior with a
primary diagnosis of schizophrenia. He had a history of significant mood symptoms, including
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severe depression with suicidal ideation. Additional diagnostic considerations had included
methamphetamine use disorder, cannabis use disorder, and alcohol use disorder by history.
Records indicated that he first received psychiatric treatment at approximately age 20 and
maintained good symptom control until he experienced significant depressive symptoms and
suicidal ideation in 2012. Records documented multiple psychiatric hospitalizations since 2012
and civil commitment as mentally ill and chemically dependent. A history of marijuana and
methamphetamine use was also documented. He had a history of suicidal ideation and behavior
but had consistently denied any suicidal ideation, intent or plan to self-harm. In 2014, he
reportedly attempted suicide by hanging which has a high potential for lethality.
He had a diagnosis of TD with severe abnormal jaw movement. He didn't remember
when this started or what medication caused it. On admission, he was not on any medications but
reported he had been on paliperidone before. He did not believe he had a mental illness hence
saw no need for medications. His treating clinician petitioned the court for an order for
involuntary treatment with antipsychotic medications and it was granted. To reduce risk of
worsening TD, he was recently started on clozapine which requires weekly lab draws. Risks and
benefits of clozapine were reviewed with him. The patient is afraid of needles and had initially
been refusing lab draws. He was agreeable to blood draws and has been compliant with taking
clozapine which has been gradually titrated to current dose of 450 mg a day.
He has been compliant and there has been noticeable improvement in his paranoia as well
as lateral jaw movement especially after his dose was titrated to 350 mg a day. Even though this
has been the case, he has been requesting different medications that don't require lab draws. This
request has created an ethical dilemma since he is on medical assistance and the newer
medications indicated for TD are expensive and would not be covered by his government issued
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insurance. Weekly labs have been normal thus far. The effectiveness of clozapine and other
newer medications/supplements in treating TD were researched. The findings are presented in
the following paragraphs.

Clozapine is considered the gold standard in treatment of refractory schizophrenia and
suicidal patients diagnosed with schizophrenia. When given in moderate doses, clozapine is
preferred in treatment of preexisting TD as it is safe and well tolerated. It has been demonstrated
as being effective in reducing abnormal movements due to its ability to bind loosely and
transiently to D2 receptors. Even though it presents serious side effects such as, agranulocytosis,
myocarditis, and seizures, its therapeutic gains have been shown to be maintained for extended
periods of time (Alam, Baruah, & Timungpi, 2015)
Clozapine is likely to increase the risk of type 2 diabetes mellitus and weight gain, in a
naturalistic study conducted on 82 patients on clozapine over a five-year period, 36.6% of
patients developed diabetes. A meta-analysis of short-term trials with clozapine indicated an
average weight gain of ten pounds over a period of ten weeks. Clozapine derives its effects from
its low D2 to serotonin ratio and also its selective preference for the mesolimbic dopamine
system (Alam et al., 2015). Mentzel et al (2018) recommended need to discontinue and replace
current antipsychotic treatment with clozapine monotherapy, a strategy that has been proved
effective in reducing TD symptoms.
Baptista and de Leon (2018) pointed out that there has not been decisive evidence to
support clozapine treatment, however, there is evidence of significant reduction in severity of TD
in many patients with moderate to severe TD. They admitted that it is unclear if clozapine treats
TD or merely suppresses its symptoms. The authors described a case where a 35-year-old
woman who developed a tardive movement disorder after starting on low dose risperidone to
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augment fluoxetine ordered for severe non-psychotic obsessive-compulsive disorder (OCD).
Improvement in OCS and abnormal movements was noted after risperidone was discontinued,
and instead a low dose of clozapine (50 mg/day) was added to a combination of fluoxetine and
clonazepam hence confirming effectiveness of clozapine in treating tardive dyskinesia.
In a retrospective study involving review of charts of 13 patients with TD who were
being treated with clozapine, there was significant improvement especially in the chronically
psychotic patients. The improvement, however, appeared to be dose-related, patients with TD at
baseline receiving 554 mg a day of clozapine had their mean AIMS score decrease by 85% over
a period of approximately 16 months (Dalack, Becks, & Meador-Woodruff, 1998). The
researchers concluded that, the clozapine effect was greater for those who were treated with
higher doses (around 300mg per day or above) and for longer periods of time, months as
opposed to weeks (Dalack et al., 1998).
In a class IV study conducted on five patients with non-psychotic illness and TD or
tardive dystonia who were put on clozapine, their AIMS reduced by at least 40% within three
weeks of treatment. In another study comprised of six patients with severe TD whose offending
medications were discontinued and clozapine in combination with clonazepam and tetrabenazine
(TBZ) were used; marked reductions in abnormal movements were noted. A six-year follow-up
using a Global Response Scale confirmed these results. Bhidayasiri, Jitkritsadakul, Friedman,
and Fahn (2018) recommended initiating clonazepam at 0.5 mg and titrating it slowly to a
maximum daily dose of 4.5 mg.
In another class IV open label, 12-month study meant to examine the effectiveness of
quetiapine, 16 patients diagnosed with psychotic or mood disorders and tardive dystonia had
their offending antipsychotics cross-tapered within the first three months. Significant
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improvement of dystonia was observed at the end of the 12-month period and there was no loss
in antipsychotic efficacy. Antipsychotics such as, haloperidol, thiopropazate, risperidone, and
olanzapine are not recommended for treatment of TD or tardive syndromes as they are known to
mask symptoms hence causing parkinsonism. It has also been noted that long-term use could
worsen TD or tardive syndrome symptoms (Bhidayasiri et al., 2018).
TD patients especially those with a polymorphism in the (brain-derived neurotrophic
factor) BDNF gene have shown great improvements after using supplement Ginkgo
biloba extract EGb-761 which contains potent antioxidant properties. Research has shown that
this supplement improves psychotic as well as EPSs when used together with haloperidol. In a
study investigating effects of Ginkgo biloba on TD patients, 157 male patients under 60 years
were started on a 12-week treatment with EGb-761 240 mg/day. Results indicated a significant
decline in AIMS score in patients with TD and there was no worsening in cognition noted and no
significant adverse effects. The researchers concluded that the antioxidant activity of extract
EGb-761 makes this supplement effective in treating schizophrenia patients exhibiting TD
symptoms (Lerner, Miodownik, & Lerner, 2015).
The maximum recommended daily dose of Ginkgo biloba is 240 mg. This supplement
has an antiplatelet effect and can cause hemorrhage; therefore, it is not recommended in patients
taking antiplatelets or anticoagulants. TBZ or amantadine is recommended as an adjuvant if
symptoms persist with Ginkgo biloba, however, patients have to be monitored for adverse effects
such as depression, parkinsonism, and visual hallucinations (Bhidayasiri et al., 2018). Vitamin E
has also been noted to prevent further deterioration of TD symptoms (Mentzel et al., 2018).
There has been no well-studied treatment for TD but there are some new medications that
have shown effectiveness. These medications include; valbenazine (Ingrezza), TBZ, and
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deutetrabenazine (Austedo). Deutetrabenazine and valbenazine are selective vascular
monoamine transporter 2 (VMAT2) inhibitors that have been recommended as well tolerated by
patients and they have longer half-lives compared to TBZ. These two medications are considered
first-line therapy approved by FDA in treating adults with TD. Their long-term benefits and
adverse effects are not known since the available clinical trials have been short-term. Atlas et al.
(2018) argued that regardless of their effectiveness, majority of TD patients are unable to obtain
them due to their high pricing.
A deuterated form of TBZ, deutetrabenazine (Deut-TBZ) has a slower breakdown of
metabolites which is advantageous in terms of ensuring a pharmacokinetic profile with a longer
metabolite duration of action. Deut-TBZ is formed through deuteration of tetrabenazine which
requires replacing six hydrogen atoms with deuterium. The half-life of the principle active
metabolite is extended, and peak plasma concentrations are reduced since deuterium bonds are
more stable than hydrogen bonds; these properties allow for once or twice per day dosing. This
also helps in tolerability that has been observed in short trials.
Tetrabenazine, on the other hand, requires frequent dosing and has been reported to have
some problematic properties such as, orthostasis during titration, sedation, and induction of
depression and suicidality (Cummings, Proctor, & Stahl, 2018). Bhidayasiri et al. (2018)
suggested use of TBZ for those patients who have no access to Deut-TBZ or valbenazine even if
there is not much evidence as there is for clonazepam or Ginkgo biloba. They further reasoned
that clonazepam or Gingko biloba can be considered as alternatives for those who fail or cannot
tolerate Deut-TBZ or valbenazine. Valbenazine was approved by FDA in 2017 as the first drug
meant for treatment of adults with TD (Uhlyar & Rey, 2018).
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In a study to examine effectiveness of Deut-TBZ in patients on antipsychotic
medications, 117 patients with moderate-to-severe TD were randomly selected from a group of
patients and then put on a 12- week treatment. A daily dose of 38.8 mg of Deut-TBZ or placebo
was randomly administered to subjects. Fifty-nine random subjects got the placebo whereas 58
got Deut-TBZ. A blinded central video was used to record AIMS scores. Results revealed that
AIMS scores decreased in patients receiving Deut-TBZ compared to those receiving placebo
(Bhidayasiri et al., 2018).
Another double-blind placebo-controlled fixed dose study conducted on 298 randomly
selected patients by European and US multicenter group meant to evaluate Deut-TBZ’s
effectiveness at doses of 12mg, 24mg, and 36mg/day revealed that Deut-TBZ was well tolerated.
Significant changes in AIMS score were noted in the 24 mg and 36 mg dose groups compared to
placebo. Results also demonstrated reduced rates of depression, somnolence, and akathisia
(Bhidayasiri et al., 2018).
Deut-TBZ’s starting dose is 6 mg once per day. It is contraindicated in suicidal
patients or those with untreated depression, hepatic impairment, or those that are on monoamine
oxidase inhibitors. Adverse reactions include neuroleptic malignant syndrome, agitation,
parkinsonism, QT prolongation, depression, and suicidality (Bhidayasiri et al., 2018). Despite the
positive effects of Deut-TBZ as relates to TD treatment, the cost of this drug is too high for
majority of patients to afford, the Institute for Clinical and Economic Review (ICER) fixed the
wholesale acquisition cost (WAC) of a daily 36-mg dose of Deut-TBZ at $90,071 (Morrow,
2018).
Valbenazine metabolizes slowly hence minimizing high peak plasma concentrations, its
half-life is long, approximately 20 hours, a property that makes it suitable to be administered
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once daily. In a randomized study, 234 subjects with TD were subjected equally to either a
placebo, 40 mg/day, or 80 mg/day of valbenazine. Persistent improvement in AIMS scores was
noted with increasing dose, maximum effect was noted at 80 mg dose. According to Bhidayasiri
et al. (2018), treatment with valbenazine did not have any effect on existing depressive
symptoms. Also, even though this treatment was associated with side effects such as,
somnolence, fatigue, headache, decreased appetite, and potentially prolonged QT interval, there
was no evidence that it caused suicidal ideation in patients with a mood disorder, schizophrenia,
or schizoaffective disorder.
Valbenazine should be avoided in patients with arrhythmias; initial dose is 40 mg once
daily (Bhidayasiri et al., 2018). The starting dose is usually administered for one week and then
increased to 80 mg, maximum dose administered once daily by mouth only. Valbenazine is very
costly and it is found only in specialty pharmacies. Patients insured under governmental, federal,
or state programs would not be able to get this medication as it is not covered. Most patients
would need 30 capsules to last them one month and wholesale price for a 40-mg strength capsule
of valbenazine is approximately $191 while that of 80-mg strength capsule goes for $208
(Uhlyar & Rey, 2018).
In a randomized, double-blind, placebo-controlled trial, 102 medically stable patients 18
to 85 years of age with clinical diagnoses of schizophrenia, schizoaffective disorder, or mood
disorder were made to remain on a stable dose of dopamine antagonist for a minimum of 30 days
before baseline. Medications such as, amantadine, tetrabenazine, anticholinergic, and
benzodiazepines were prohibited. Patients were randomly divided into two groups; one group
was started on valbenazine which was initiated at 25 mg and titrated 25 mg every two weeks to a
maximum of 75 mg per day as tolerated. The second group was placed on a placebo. At six
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weeks, researchers observed a mean reduction of 2.4 points on the AIMS in patients with
moderate-to-severe TD taking valbenazine. After another six weeks, a mean reduction in AIMS
score of 3.2 was noted in patients taking daily valbenazine dose of 80 mg (Uhlyar & Rey, 2018).
Financial dilemma for most patients presents a challenge to providers who are forced to
make a decision to proceed with alternative treatment that costs less. There is need to advocate
for safety net institutions where patients can receive subsidized or free treatment of their choice.
Weiner (2001) noted that providers may unknowingly commit technical violations or be engaged
in abuse or fraud in their efforts to accommodate patients with health insurance coverages that do
not cover needed treatments or services. These violations may result from not billing at all,
undercoding, waiving deductibles, or reducing charges below their usual fee.
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